This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
PEACE-3 Trial
PROfound Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
VISION Trial
mHSPC
ARANOTE Trial
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA Trial
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
CORE-001 Study
ADSTILADRIN
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
Decipher Genomic Classifier
Imaging Center
Phillip Koo, MD
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
mCRPC Treatment
A. Oliver Sartor, MD
PSMA-Targeted Therapy
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
Masofaniten (EPI-7386)
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
ASTRO 2024
IBCN 2024
ESMO 2024
BCAN TT 2024
ASCO 2024
All Conferences
View All
PCF
UroToday Home
Conference Highlights
ASCO GU 2018
ASCO GU 2018
Prostate Cancer
Bladder Cancer
Renal Cancer
Penile, Urethral, Testicular and Adrenal Cancers
Press
ASCO GU 2018 Prostate Cancer
Viewing 41-60 of 88 articles
ASCO GU 2018: Outcomes in Patients with Advanced Prostate Cancer And Inactivating Germline Mutations in BRCA2 or ATM
ASCO GU 2018: Incorporating Genomics Into the Management of Systemic Therapy: Advances and Practicality
ASCO GU 2018: Impact of Sexual Orientation on Contemporary Rates of Prostate Cancer Screening
ASCO GU 2018: Why are Low-risk Prostate Cancers (Pca) Treated Aggressively? A Population-based Cohort Analysis
ASCO GU 2018: Statin use and Outcomes of Patients with mCRPC Being Treated with Abiraterone
ASCO GU 2018: A National Survey of Radiation Oncologists and Urologists on Active Surveillance for Low-risk Prostate Cancer
ASCO GU 2018: When Can Active Surveillance Be Less Active? Prediction of Long-term Non-reclassification for Men with Low-risk Prostate Cancer
ASCO GU 2018: TPS 159 -What Fixes PSA Screening Guidelines Gone Wrong?
ASCO GU 2018: Can free PSA be used as a biomarker in biochemical recurrence after surgery to predict CRPC?
ASCO GU 2018: Radium-223 Retreatment in an International, Open-label, Phase I/II Study in Patients with CRPC and Bone Metastases: 2-year Follow-up
ASCO GU 2018: Abiraterone acetate plus prednisone 5 mg daily in metastatic castration-naïve prostate cancer (mCNPC): Detailed safety analyses from the LATITUDE phase III trial
ASCO GU 2018: Enzalutamide vs Bicalutamide in Combination with Androgen Deprivation in mHSPC
ASCO GU 2018: Indirect Treatment Comparison of Abiraterone Acetate Plus Prednisone and Docetaxel on Patient-reported Outcomes in Metastatic Castration-naïve Prostate Cancer (mCNPC)
ASCO GU 2018: Overall Survival of Patients with Metastatic Prostate Cancer Starting ADT with Degarelix, A Gonadotropin-releasing Hormone Antagonist
ASCO GU 2018: The Clinical Role of Germline and Somatic Genomics and the Risk-Stratification of Localized Prostate Cancer
ASCO GU 2018: DNA Repair Gene Panel Mutations in Young Onset Prostate Cancer Cases in The United Kingdom
ASCO GU 2018: Visceral Metastases on Abiraterone vs. Placebo: A Post-hoc Analysis of Mode of Radiographic Progression In COU-AA-302
ASCO GU 2018: Occurrence of pathologic stage T3 disease at radical prostatectomy with ISUP grade group 1 (Gleason 3+3=6) prostate cancer
ASCO GU 2018: Optimal Timing of Post-prostatectomy Radiotherapy For Prostate Cancer With High-risk Pathologic Features: A Multi-institutional Analysis
ASCO GU 2018: Evaluation of a Predefined as Threshold in a Large Cohort of Men with Localized Prostate Cancer
1
2
3
4
5
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free